HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival.

Abstract
We examined the relationship of axillary level of lymph node metastases from clinical stage I and II breast cancer to overall survival and disease-free survival rates in 135 patients who underwent complete axillary lymph node dissection to determine if anatomic level of axillary involvement (I vs II vs III) is an independent prognostic factor. All patients underwent either modified radical mastectomy or lumpectomy with axillary dissection and whole breast radiotherapy for breast cancer. Median follow-up was 6.9 years. We found no difference in overall survival or disease-free survival between patients whose highest or only level of axillary involvement was level I compared with patients whose highest or only level was II. Although patients whose highest level of nodal involvement was III had significantly worse overall survival and disease-free survival rates than patients whose highest nodal involvement was I or II, when patients were stratified by the total number of positive nodes (one to three vs four or more), there was no difference in overall survival or disease-free survival rates between levels I, II, and III. These findings indicate that the level of axillary involvement for stage II breast cancer is not of independent prognostic significance.
AuthorsR J Barth Jr, D N Danforth Jr, D J Venzon, K L Straus, T d'Angelo, M J Merino, L Gerber
JournalArchives of surgery (Chicago, Ill. : 1960) (Arch Surg) Vol. 126 Issue 5 Pg. 574-7 (May 1991) ISSN: 0004-0010 [Print] United States
PMID2021339 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Axilla
  • Breast Neoplasms (mortality, pathology, surgery)
  • Female
  • Follow-Up Studies
  • Humans
  • Lymph Node Excision (mortality)
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis (pathology)
  • Maryland (epidemiology)
  • Middle Aged
  • Neoplasm Staging
  • Postoperative Care
  • Prognosis
  • Prospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: